SDZ.SW SANDOZ GROUP N | CH1243598427
Company Profile
Sandoz Group AG develops, manufactures, and markets generic and biosimilars worldwide. The company covers therapeutic areas, including cardiovascular, central nervous system, oncology, infectious diseases, pain and respiratory, supportive care, rare diseases, diabetes, immunology, endocrinology, neurology, osteoporosis, nephrology, hematology, and ophthalmology. It also provides a portfolio of active pharmaceutical ingredients and finished dosage forms. Sandoz Group AG was founded in 1886 and is headquartered in Basel, Switzerland.
Latest News
| Sector | Healthcare |
| Industry | Drug Manufacturers - Specialty & Generic |
| Website | https://www.sandoz.com |
| Audit Risk | 9 |
| Board Risk | 1 |
| Overall Risk | 2 |
| Market Cap | 27.65B |
| Trailing P/E | 37.37 |
| Forward P/E | 16.92 |
| Dividend Rate | 0.8 |
| Dividend Yield | 1.26% |
| Trailing Annual Div. Rate | 1.01 |
| Trailing Annual Div. Yield | 1.59% |
| Trailing EPS | 1.71 |
| Forward EPS | 3.78 |
| Book Value | 17.57 |
| Price-to-Book | 3.64 |
| Enterprise-to-Revenue | 2.82 |
| Enterprise-to-EBITDA | 16.64 |
| Ex-Dividend Date | 04/13/2026 |
| Dividend Date | 04/23/2025 |
| Earnings Date | |
| Earnings Call Date | |
| Revenue Average | 2.75B |
| Revenue Low | 2.75B |
| Revenue High | 2.75B |